Aptevo Therapeutics Inc
APVO
NASDAQ
Biotechnology
$2.94
USD
-0.46 (-13.53%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.16M
Volume 79.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-26.26M
TTM
-10.8%
YoY
Operating Cash Flow
$-26.98M
TTM
-13.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.8 | 2.9 | 3.6 | 2.5 | 2.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.5 | 6.2 | 7.6 | 6.0 | 6.8 |
Operating Income | -6.5 | -6.2 | -7.6 | -6.0 | -6.8 |
EBITDA | -6.4 | -6.2 | -7.6 | -5.9 | -6.8 |
Other Income / Expense | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 |
Total Other Income / Expense | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 |
Income Before Income Taxes | -6.4 | -6.2 | -7.5 | -5.8 | -6.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.4 | -6.2 | -7.5 | -5.8 | -6.7 |
Consolidated Net Income / Loss | -6.4 | -6.2 | -7.5 | -5.8 | -6.7 |
Net Income Attributable to Common Shareholders | -6.4 | -6.2 | -9.0 | -5.9 | -6.7 |
Basic EPS | -$1,581.81 | -$151.20 | -$40.14 | -$5.94 | -$6.41 |
Diluted EPS | -$1,581.81 | -$151.20 | -$40.14 | -$5.94 | -$6.41 |
Basic Shares Outstanding | 0.0M | 0.0M | 0.2M | 1.0M | 1.1M |
Diluted Shares Outstanding | 0.0M | 0.0M | 0.2M | 1.0M | 1.1M |